참고문헌
- Anand R, Gill KD and Mahdi AA (2014) Therapeutics of Alzheimer's disease: Past, present and future. Neuropharmacology 76 Pt A, 27-50 https://doi.org/10.1016/j.neuropharm.2013.07.004
- Perry G, Nunomura A, Hirai K, Takeda A, Aliev G and Smith MA (2000) Oxidative damage in Alzheimer's disease: the metabolic dimension. Int J Dev Neurosci 18, 417-421 https://doi.org/10.1016/S0736-5748(00)00006-X
- Schmitt K, Grimm A, Kazmierczak A, Strosznajder JB, Gotz J and Eckert A (2012) Insights into mitochondrial dysfunction: aging, amyloid-beta, and tau-A deleterious trio. Antioxid Redox Signal 16, 1456-1466 https://doi.org/10.1089/ars.2011.4400
- Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT and Brinton RD (2009) Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 106, 14670-14675 https://doi.org/10.1073/pnas.0903563106
- Swerdlow RH, Burns JM and Khan SM (2010) The Alzheimer's disease mitochondrial cascade hypothesis. J Alzheimers Dis 20 Suppl 2, S265-279
- Hauptmann S, Scherping I, Drose S et al (2009) Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging 30, 1574-1586 https://doi.org/10.1016/j.neurobiolaging.2007.12.005
- Shulman RG, Rothman DL, Behar KL and Hyder F (2004) Energetic basis of brain activity: implications for neuroimaging. Trends Neurosci 27, 489-495 https://doi.org/10.1016/j.tins.2004.06.005
- Mao P and Reddy PH (2011) Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: implications for early intervention and therapeutics. Biochim Biophys Acta 1812, 1359-1370 https://doi.org/10.1016/j.bbadis.2011.08.005
- Keil U, Bonert A, Marques CA et al (2004) Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J Biol Chem 279, 50310-50320 https://doi.org/10.1074/jbc.M405600200
- Eckert GP, Renner K, Eckert SH et al (2012) Mitochondrial dysfunction-a pharmacological target in Alzheimer's disease. Mol Neurobiol 46, 136-150 https://doi.org/10.1007/s12035-012-8271-z
- Johri A and Beal MF (2012) Mitochondrial dysfunction in neurodegenerative diseases. J Pharmacol Exp Ther 342, 619-630 https://doi.org/10.1124/jpet.112.192138
- Moreira PI, Carvalho C, Zhu X, Smith MA and Perry G (2010) Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. Biochim Biophys Acta 1802, 2-10 https://doi.org/10.1016/j.bbadis.2009.10.006
- Muller WE, Eckert A, Kurz C, Eckert GP and Leuner K (2010) Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer's disease-therapeutic aspects. Mol Neurobiol 41, 159-171 https://doi.org/10.1007/s12035-010-8141-5
- Swerdlow RH, Burns JM and Khan SM (2014) The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. Biochim Biophys Acta 1842, 1219-1231 https://doi.org/10.1016/j.bbadis.2013.09.010
- Farlow MR, Miller ML and Pejovic V (2008) Treatment options in Alzheimer's disease: maximizing benefit, managing expectations. Dement Geriatr Cogn Disord 25, 408-422 https://doi.org/10.1159/000122962
- Moehle EA, Shen K and Dillin A (2019) Mitochondrial proteostasis in the context of cellular and organismal health and aging. J Biol Chem 294, 5396-5407 https://doi.org/10.1074/jbc.tm117.000893
- Tatsuta T and Langer T (2008) Quality control of mitochondria: protection against neurodegeneration and ageing. EMBO J 27, 306-314 https://doi.org/10.1038/sj.emboj.7601972
- Franco-Iborra S, Vila M and Perier C (2018) Mitochondrial Quality Control in Neurodegenerative Diseases: Focus on Parkinson's Disease and Huntington's Disease. Front Neurosci 12, 342 https://doi.org/10.3389/fnins.2018.00342
- Tilokani L, Nagashima S, Paupe V and Prudent J (2018) Mitochondrial dynamics: overview of molecular mechanisms. Essays Biochem 62, 341-360 https://doi.org/10.1042/EBC20170104
- Burte F, Carelli V, Chinnery PF and Yu-Wai-Man P (2015) Disturbed mitochondrial dynamics and neurodegenerative disorders. Nat Rev Neurol 11, 11-24 https://doi.org/10.1038/nrneurol.2014.228
- Kandimalla R and Reddy PH (2016) Multiple faces of dynamin-related protein 1 and its role in Alzheimer's disease pathogenesis. Biochim Biophys Acta 1862, 814-828 https://doi.org/10.1016/j.bbadis.2015.12.018
- Reddy PH and Beal MF (2008) Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med 14, 45-53 https://doi.org/10.1016/j.molmed.2007.12.002
- Manczak M and Reddy PH (2012) Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer's disease neurons: implications for mitochondrial dysfunction and neuronal damage. Hum Mol Genet 21, 2538-2547 https://doi.org/10.1093/hmg/dds072
- Silva DF, Selfridge JE, Lu J et al (2013) Bioenergetic flux, mitochondrial mass and mitochondrial morphology dynamics in AD and MCI cybrid cell lines. Hum Mol Genet 22, 3931-3946 https://doi.org/10.1093/hmg/ddt247
- Calkins MJ, Manczak M, Mao P, Shirendeb U and Reddy PH (2011) Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Hum Mol Genet 20, 4515-4529 https://doi.org/10.1093/hmg/ddr381
- Manczak M, Calkins MJ and Reddy PH (2011) Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. Hum Mol Genet 20, 2495-2509 https://doi.org/10.1093/hmg/ddr139
- Cassidy-Stone A, Chipuk JE, Ingerman E et al (2008) Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. Dev Cell 14, 193-204 https://doi.org/10.1016/j.devcel.2007.11.019
- Wang W, Yin J, Ma X et al (2017) Inhibition of mitochondrial fragmentation protects against Alzheimer's disease in rodent model. Hum Mol Genet 26, 4118-4131 https://doi.org/10.1093/hmg/ddx299
- Baek SH, Park SJ, Jeong JI et al (2017) Inhibition of Drp1 Ameliorates Synaptic Depression, Abeta Deposition, and Cognitive Impairment in an Alzheimer's Disease Model. J Neurosci 37, 5099-5110 https://doi.org/10.1523/JNEUROSCI.2385-16.2017
- Guo X, Disatnik MH, Monbureau M, Shamloo M, Mochly-Rosen D and Qi X (2013) Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration. J Clin Invest 123, 5371-5388 https://doi.org/10.1172/JCI70911
- Qi X, Qvit N, Su YC and Mochly-Rosen D (2013) A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity. J Cell Sci 126, 789-802 https://doi.org/10.1242/jcs.114439
- Numadate A, Mita Y, Matsumoto Y, Fujii S and Hashimoto Y (2014) Development of 2-thioxoquinazoline-4-one derivatives as dual and selective inhibitors of dynaminrelated protein 1 (Drp1) and puromycin-sensitive aminopeptidase (PSA). Chem Pharm Bull (Tokyo) 62, 979-988 https://doi.org/10.1248/cpb.c14-00333
- Mallat A, Uchiyama LF, Lewis SC et al (2018) Discovery and characterization of selective small molecule inhibitors of the mammalian mitochondrial division dynamin, DRP1. Biochem Biophys Res Commun 499, 556-562 https://doi.org/10.1016/j.bbrc.2018.03.189
- Kuruva CS, Manczak M, Yin X, Ogunmokun G, Reddy AP and Reddy PH (2017) Aqua-soluble DDQ reduces the levels of Drp1 and Abeta and inhibits abnormal interactions between Abeta and Drp1 and protects Alzheimer's disease neurons from Abeta- and Drp1-induced mitochondrial and synaptic toxicities. Hum Mol Genet 26, 3375-3395 https://doi.org/10.1093/hmg/ddx226
- Smith G and Gallo G (2017) To mdivi-1 or not to mdivi-1: Is that the question? Dev Neurobiol 77, 1260-1268 https://doi.org/10.1002/dneu.22519
- Valente EM, Abou-Sleiman PM, Caputo V et al (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158-1160 https://doi.org/10.1126/science.1096284
- Pickrell AM and Youle RJ (2015) The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron 85, 257-273 https://doi.org/10.1016/j.neuron.2014.12.007
- Du F, Yu Q, Yan S et al (2017) PINK1 signalling rescues amyloid pathology and mitochondrial dysfunction in Alzheimer's disease. Brain 140, 3233-3251 https://doi.org/10.1093/brain/awx258
- Fang EF, Hou Y, Palikaras K et al (2019) Mitophagy inhibits amyloid-beta and tau pathology and reverses cognitive deficits in models of Alzheimer's disease. Nat Neurosci 22, 401-412 https://doi.org/10.1038/s41593-018-0332-9
- Andreux PA, Blanco-Bose W, Ryu D et al (2019) The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab 1, 595 https://doi.org/10.1038/s42255-019-0073-4
- Lambourne OA and Mehellou Y (2018) Chemical Strategies for Activating PINK1, a Protein Kinase Mutated in Parkinson's Disease. Chembiochem 19, 2433-2437 https://doi.org/10.1002/cbic.201800497
- Hertz NT, Berthet A, Sos ML et al (2013) A neo-substrate that amplifies catalytic activity of parkinson's-diseaserelated kinase PINK1. Cell 154, 737-747 https://doi.org/10.1016/j.cell.2013.07.030
- Osgerby L, Lai YC, Thornton PJ et al (2017) Kinetin Riboside and Its ProTides Activate the Parkinson's Disease Associated PTEN-Induced Putative Kinase 1 (PINK1) Independent of Mitochondrial Depolarization. J Med Chem 60, 3518-3524 https://doi.org/10.1021/acs.jmedchem.6b01897
- Barini E, Miccoli A, Tinarelli F et al (2018) The Anthelmintic Drug Niclosamide and Its Analogues Activate the Parkinson's Disease Associated Protein Kinase PINK1. Chembiochem 19, 425-429 https://doi.org/10.1002/cbic.201700500
- Halestrap AP (2009) What is the mitochondrial permeability transition pore? J Mol Cell Cardiol 46, 821-831 https://doi.org/10.1016/j.yjmcc.2009.02.021
- Baines CP, Kaiser RA, Purcell NH et al (2005) Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 434, 658-662 https://doi.org/10.1038/nature03434
- Du H, Guo L, Fang F et al (2008) Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med 14, 1097-1105 https://doi.org/10.1038/nm.1868
- Du H, Guo L, Zhang W, Rydzewska M and Yan S (2011) Cyclophilin D deficiency improves mitochondrial function and learning/memory in aging Alzheimer disease mouse model. Neurobiol Aging 32, 398-406 https://doi.org/10.1016/j.neurobiolaging.2009.03.003
- Briston T, Selwood DL, Szabadkai G and Duchen MR (2019) Mitochondrial Permeability Transition: A Molecular Lesion with Multiple Drug Targets. Trends Pharmacol Sci 40, 50-70 https://doi.org/10.1016/j.tips.2018.11.004
- Elkamhawy A, Lee J, Park BG, Park I, Pae AN and Roh EJ (2014) Novel quinazoline-urea analogues as modulators for Abeta-induced mitochondrial dysfunction: design, synthesis, and molecular docking study. Eur J Med Chem 84, 466-475 https://doi.org/10.1016/j.ejmech.2014.07.027
- Valasani KR, Sun Q, Fang D et al (2016) Identification of a Small Molecule Cyclophilin D Inhibitor for Rescuing Abeta-Mediated Mitochondrial Dysfunction. ACS Med Chem Lett 7, 294-299 https://doi.org/10.1021/acsmedchemlett.5b00451
- Valasani KR, Vangavaragu JR, Day VW and Yan SS (2014) Structure based design, synthesis, pharmacophore modeling, virtual screening, and molecular docking studies for identification of novel cyclophilin D inhibitors. J Chem Inf Model 54, 902-912 https://doi.org/10.1021/ci5000196
- Park I, Londhe AM, Lim JW et al (2017) Discovery of non-peptidic small molecule inhibitors of cyclophilin D as neuroprotective agents in Abeta-induced mitochondrial dysfunction. J Comput Aided Mol Des 31, 929-941 https://doi.org/10.1007/s10822-017-0067-9
- Paul SM and Purdy RH (1992) Neuroactive steroids. FASEB J 6, 2311-2322 https://doi.org/10.1096/fasebj.6.6.1347506
- Porcu P, Barron AM, Frye CA et al (2016) Neurosteroidogenesis Today: Novel Targets for Neuroactive Steroid Synthesis and Action and Their Relevance for Translational Research. J Neuroendocrinol 28, 12351
- Rupprecht R, Papadopoulos V, Rammes G et al (2010) Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov 9, 971-988 https://doi.org/10.1038/nrd3295
- Banati RB, Middleton RJ, Chan R et al (2014) Positron emission tomography and functional characterization of a complete PBR/TSPO knockout. Nat Commun 5, 5452 https://doi.org/10.1038/ncomms6452
- Li J, Wang J and Zeng Y (2007) Peripheral benzodiazepine receptor ligand, PK11195 induces mitochondria cytochrome c release and dissipation of mitochondria potential via induction of mitochondria permeability transition. Eur J Pharmacol 560, 117-122 https://doi.org/10.1016/j.ejphar.2006.12.027
- Sileikyte J, Blachly-Dyson E, Sewell R et al (2014) Regulation of the mitochondrial permeability transition pore by the outer membrane does not involve the peripheral benzodiazepine receptor (Translocator Protein of 18 kDa (TSPO)). J Biol Chem 289, 13769-13781 https://doi.org/10.1074/jbc.M114.549634
- Selvaraj V and Stocco DM (2015) The changing landscape in translocator protein (TSPO) function. Trends Endocrinol Metab 26, 341-348 https://doi.org/10.1016/j.tem.2015.02.007
- Barron AM, Garcia-Segura LM, Caruso D et al (2013) Ligand for translocator protein reverses pathology in a mouse model of Alzheimer's disease. J Neurosci 33, 8891-8897 https://doi.org/10.1523/JNEUROSCI.1350-13.2013
- Kim T, Yang HY, Park BG et al (2017) Discovery of benzimidazole derivatives as modulators of mitochondrial function: A potential treatment for Alzheimer's disease. Eur J Med Chem 125, 1172-1192 https://doi.org/10.1016/j.ejmech.2016.11.017
- Monga S, Nagler R, Amara R, Weizman A and Gavish M (2019) Inhibitory Effects of the Two Novel TSPO Ligands 2-Cl-MGV-1 and MGV-1 on LPS-induced Microglial Activation. Cells 8, 486 https://doi.org/10.3390/cells8050486
- Yang SY, He XY and Miller D (2011) Hydroxysteroid (17beta) dehydrogenase X in human health and disease. Mol Cell Endocrinol 343, 1-6 https://doi.org/10.1016/j.mce.2011.06.011
- Yang SY, He XY, Isaacs C, Dobkin C, Miller D and Philipp M (2014) Roles of 17beta-hydroxysteroid dehydrogenase type 10 in neurodegenerative disorders. J Steroid Biochem Mol Biol 143, 460-472 https://doi.org/10.1016/j.jsbmb.2014.07.001
- He XY, Wegiel J and Yang SY (2005) Intracellular oxidation of allopregnanolone by human brain type 10 17beta-hydroxysteroid dehydrogenase. Brain Res 1040, 29-35 https://doi.org/10.1016/j.brainres.2005.01.022
- Lustbader JW, Cirilli M, Lin C et al (2004) ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304, 448-452 https://doi.org/10.1126/science.1091230
- Morsy A and Trippier PC (2019) Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease. J Med Chem 62, 4252-4264 https://doi.org/10.1021/acs.jmedchem.8b01530
- Boutin S, Roy J, Maltais R, Alata W, Calon F and Poirier D (2018) Identification of steroidal derivatives inhibiting the transformations of allopregnanolone and estradiol by 17beta-hydroxysteroid dehydrogenase type 10. Bioorg Med Chem Lett 28, 3554-3559 https://doi.org/10.1016/j.bmcl.2018.09.031
- Lim YA, Grimm A, Giese M et al (2011) Inhibition of the mitochondrial enzyme ABAD restores the amyloid-betamediated deregulation of estradiol. PLoS One 6, e28887 https://doi.org/10.1371/journal.pone.0028887
- Valasani KR, Hu G, Chaney MO and Yan SS (2013) Structure-based design and synthesis of benzothiazole phosphonate analogues with inhibitors of human ABAD-Abeta for treatment of Alzheimer's disease. Chem Biol Drug Des 81, 238-249 https://doi.org/10.1111/cbdd.12068
- Benek O, Hroch L, Aitken L et al (2017) 6-benzothiazolyl ureas, thioureas and guanidines are potent inhibitors of ABAD/17beta-HSD10 and potential drugs for Alzheimer's disease treatment: Design, synthesis and in vitro evaluation. Med Chem 13, 345-358 https://doi.org/10.2174/1573406413666170109142725
- Viswanath ANI, Kim T, Jung SY, Lim SM and Pae AN (2017) In silico-designed novel non-peptidic ABAD LD hot spot mimetics reverse Abeta-induced mitochondrial impairments in vitro. Chem Biol Drug Des 90, 1041-1055 https://doi.org/10.1111/cbdd.13065
- Holmstrom KM and Finkel T (2014) Cellular mechanisms and physiological consequences of redox-dependent signalling. Nat Rev Mol Cell Biol 15, 411-421 https://doi.org/10.1038/nrm3801
- Tonnies E and Trushina E (2017) Oxidative Stress, Synaptic Dysfunction, and Alzheimer's Disease. J Alzheimers Dis 57, 1105-1121 https://doi.org/10.3233/JAD-161088
- Cheignon C, Tomas M, Bonnefont-Rousselot D, Faller P, Hureau C and Collin F (2018) Oxidative stress and the amyloid beta peptide in Alzheimer's disease. Redox Biol 14, 450-464 https://doi.org/10.1016/j.redox.2017.10.014
- Barnham KJ and Bush AI (2014) Biological metals and metal-targeting compounds in major neurodegenerative diseases. Chem Soc Rev 43, 6727-6749 https://doi.org/10.1039/C4CS00138A
- Dumont M, Kipiani K, Yu F et al (2011) Coenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 27, 211-223 https://doi.org/10.3233/JAD-2011-110209
- Gugliandolo A, Bramanti P and Mazzon E (2017) Role of Vitamin E in the Treatment of Alzheimer's Disease: Evidence from Animal Models. Int J Mol Sci 18, 2504 https://doi.org/10.3390/ijms18122504
- McManus MJ, Murphy MP and Franklin JL (2011) The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease. J Neurosci 31, 15703-15715 https://doi.org/10.1523/JNEUROSCI.0552-11.2011
- Covey MV, Murphy MP, Hobbs CE, Smith RA and Oorschot DE (2006) Effect of the mitochondrial antioxidant, Mito Vitamin E, on hypoxic-ischemic striatal injury in neonatal rats: a dose-response and stereological study. Exp Neurol 199, 513-519 https://doi.org/10.1016/j.expneurol.2005.12.026
- Webb M, Sideris DP and Biddle M (2019) Modulation of mitochondrial dysfunction for treatment of disease. Bioorg Med Chem Lett 29, 1270-1277 https://doi.org/10.1016/j.bmcl.2019.03.041
- Oliver DMA and Reddy PH (2019) Small molecules as therapeutic drugs for Alzheimer's disease. Mol Cell Neurosci 96, 47-62 https://doi.org/10.1016/j.mcn.2019.03.001
- El-Hattab AW, Zarante AM, Almannai M and Scaglia F (2017) Therapies for mitochondrial diseases and current clinical trials. Mol Genet Metab 122, 1-9